Minimal Residual Disease in Peripheral T-cell Lymphoma

Status:	Recruiting
Conditions:	Lymphoma
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	4/6/2019
Start Date:	July 31, 2017
End Date:	July 31, 2021
Contact:	Neha Mehta-Shah, M.D.
Email:	mehta-n@wustl.edu
Phone:	314-273-1070

A Multi-Institutional Prospective Cohort Study of Minimal Residual Disease in Peripheral T-cell Lymphoma

As T-cell receptor sequencing by LymphoTrack is an assay with high sensitivity that can be
performed in peripheral blood, the investigators wish to evaluate the ability of this assay
to predict which patients are at higher risk of relapse after initial therapy for peripheral
T-cell lymphomas which is being given for curative intent. Additionally, as more is known
about the ability of dynamic monitoring of cfDNA in B-cell lymphomas to predict relapse, the
investigators wish to explore the use of this technology in T-cell lymphomas.

Inclusion Criteria:

- At least 18 years of age.

- Histologically-confirmed peripheral T-cell lymphoma being treated with curative
intent. Eligible histologies include: peripheral T-cell lymphoma, not otherwise
specified; angioimmunoblastic T-cell lymphoma; anaplastic large cell lymphoma, ALK
negative; and anaplastic large cell lymphoma, ALK positive.

- Plan for treatment with frontline multi-agent anthracycline containing chemotherapy
for curative intent (for example, CHOP, CHOEP, EPOCH). A frontline therapy program can
include different sequential phases of treatment, including high-dose therapy and
autologous stem cell transplantation.

- Availability of pre-treatment test specimen from bone marrow, blood, lymph node, or
alternate site to identify tumor-specific clonotype, or willingness to undergo biopsy
if sufficient tissue is not available at time of enrollment (e.g. 15 slides from fixed
formalin-fixed paraffin embedded tumor tissue

*Patients who have less than 15 slides of fixed formalin-fixed paraffin embedded tumor
tissue may be considered for enrollment after discussion with the study principal
investigator

- Able to understand and willing to sign an IRB approved written informed consent
document.

Exclusion Criteria:

- Receiving second line of therapy or greater.

- Diagnosis of primary cutaneous T-cell lymphoma, extranodal NK-cell lymphoma, acute
T-cell lymphoma/leukemia, hepatosplenic T-cell lymphoma.

We found this trial at

sites

Washington University School of Medicine

660 S Euclid Ave
Saint Louis, Missouri 63110

(314) 362-5000